Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Ascelia Pharma AB ( (SE:ACE) ).
Ascelia Pharma AB announced a change in its share structure due to the conversion of 53,335 series C shares into ordinary shares as part of a performance-based share saving program. This adjustment results in a total of 127,902,580 shares, impacting the company’s voting structure and reflecting its ongoing commitment to aligning stakeholder interests.
More about Ascelia Pharma AB
Ascelia Pharma is a biotech company focused on developing and commercializing orphan oncology treatments to address unmet medical needs. The company is headquartered in Malmö, Sweden, and is listed on Nasdaq Stockholm. Its primary drug candidates are Orviglance and Oncoral.
Average Trading Volume: 1,567,226
Technical Sentiment Signal: Sell
Current Market Cap: SEK329.1M
See more data about ACE stock on TipRanks’ Stock Analysis page.